Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance.

Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 1999 Mar 15; 93(6):2075-80.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.